ROCKVILLE, Md.--(BUSINESS WIRE)--On Monday, March 6, Immunomic Therapeutics, Inc. (ITI) CEO Bill Hearl, Ph.D., will participate in a panel discussion on vaccines and infectious disease at the 10th Annual European Life Science CEO Forum and Exhibition. Dr. Hearl will be discussing the future of vaccines and Immunomic’s unique LAMP-Vax™ technology platform. LAMP-Vax is an exclusive immunotherapy technology that works with the body’s natural biochemistry system and has the potential to make any vaccine more effective.
Who: Immunomic Therapeutics, Inc. CEO Bill Hearl, Ph.D.
What: Vaccine and Infectious Disease panel discussion during the 10th Annual European Life Science CEO Forum and Exhibition.
When: March 6, 2017, 10:45 am UTC
Where: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Switzerland
Immunomic Therapeutics, Inc. is a privately-held, clinical stage biotech company on a mission to pioneer vaccines that transform lives. The company, based in Rockville, MD, is developing nucleic acid vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) Technology. Termed LAMP-Vax™, the exclusive immunotherapy technology works with the body’s natural biochemistry system and has the potential to improve a broad range of vaccines. ITI entered into a licensing agreement with Astellas Pharma Inc. in 2015 to explore the use of LAMP-Vax in the prevention and treatment of allergic diseases, and is now focused on cancer immunotherapy. The LAMP platform has been tested in Phase I and II clinical studies. For more information, please visit www.immunomix.com.
